 |
  
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Press Release New 600-mg Tablet Strength for Prezista (Darunavir)February 26, 2008 On February 25, 2008, FDA approved a new 600-mg tablet strength for Prezista (darunavir), manufactured by Tibotec, Inc., Yardley, PA. The new 600-mg tablet facilitates dosing by reducing pill burden. The recommended oral dose of Prezista tablets is 600 mg (two 300-mg tablets or one 600-mg tablet) twice daily taken with ritonavir 100 mg twice daily and with food. The 600-mg formulation will be available in bottles of 60 tablets. Darunavir is a protease inhibitor, which inhibits the formation of mature virus in HIV infected cells. [Editor's note from TheBody.com: The 600-mg tablet is not expected to be available in the United States until mid-May 2008, according to a Tibotec official. The official also noted that the price of the new tablet will be the same as two of the 300-mg tablets.]  This article was provided by U.S. Food and Drug Administration.
|
 |
Email
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
